Stat6 aso
WebDec 3, 2024 · In data recently presented at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024), exoASO-STAT6 was observed to induce significant and prolonged reduction of STAT6 mRNA in hepatocellular carcinoma models, attenuate tumor growth, and induce complete remission of tumor lesions in 50% of mice. WebJun 29, 2024 · In multiple in vivo preclinical studies, exoASO-STAT6 demonstrated potent single agent activity, including >90% tumor growth inhibition and 50-80% complete responses. In HCC models, exoASO-STAT6 induced significant knockdown of STAT6 mRNA, attenuated tumor growth and induced complete remission of tumor lesions in 50% of mice.
Stat6 aso
Did you know?
WebConclusions In summary, we demonstrated that exoASO-STAT6 has a durable PK/PD profile in the liver of preclinical species, identified PD biomarkers with good clinical translational … WebFeb 28, 2024 · ExoASO-STAT6 is under clinical development by Codiak BioSciences and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for …
WebJun 29, 2024 · In multiple in vivo preclinical studies, exoASO-STAT6 demonstrated potent single agent activity, including >90% tumor growth inhibition and 50-80% complete …
WebMay 11, 2024 · ASO-STAT6 exosome administered Intravenously Arms, Groups and Cohorts Experimental: Experimental CDK-004 CDK-004 administered as a single agent intravenously (IV) on Days 1 and 15 of Cycles 1 and 2, on Day 1 of every Cycle. Clinical Trial Outcome Measures Primary Measures To characterize the safety and tolerability of CDK-004. WebPK analysis showed that the STAT6-ASO is rapidly cleared from plasma. Retention of the ASO in liver was dose-dependent and observed for at least 21 days. exoASO-STAT6 induced significant Stat6 mRNA knockdown (KD) in liver tissue with maximum KD at day 7 (70% KD at the 30 ug dose).
WebFeb 18, 2024 · This novel engineered exosome, exoASO-STAT6, demonstrates maximal biodistribution and STAT6-silencing activity in the liver after intravenous administration, with minimal effects in other tissues. exoASO-STAT6 shows robust antitumor activity as a monotherapy in multiple preclinical tumor models by inducing remodeling of the TME.
WebFeb 18, 2024 · We describe an engineered exosome therapeutic candidate delivering an antisense oligonucleotide (ASO) targeting STAT6 (exoASO-STAT6), which selectively … nbc\u0027s rival crossword clueWebDec 3, 2024 · Preclinical studies of exoASO-STAT6 showed single agent anti-tumor activity in models of aggressive hepatocellular carcinoma. “This is an important milestone for … marriage license for north carolinaWeb戊型肝炎病毒IgG（HEV-IgG）检测试剂盒典型操作流程： 1. 戊型肝炎病毒IgG（HEV-IgG）检测试剂盒从室温平衡20min后的铝箔袋中取出所需板条，剩余板条用自封袋密封放回4℃。 marriage license from texasWebJun 30, 2024 · In HCC models, exoASO-STAT6 induced significant knockdown of STAT6 mRNA, attenuated tumor growth and induced complete remission of tumor lesions in 50% … nbc\\u0027s peacock streaming serviceWebFeb 23, 2024 · Therefore, we targeted STAT6 using an antisense oligonucleotide (ASO) along with hypofractionated RT (hRT; 3 fractions of 12 Gy each) to primary tumors in three bilateral murine NSCLC models (Lewis lung carcinoma, 344SQ-parental, and anti–PD-1–resistant 344SQ lung adenocarcinomas). marriage license galveston county txWebNov 17, 2024 · ExoASO STAT6 is an engineered exosomes, surface loaded with an antisense oligonucleotide (ASO) targeting immune suppressive macrophages (M2) and monocytes, exoASO STAT6 ... exoASO STAT6 Alternative Names: CDK 004; exoASO™-STAT6 Latest Information Update: 17 Nov 2024. Price : $50 * Buy Profile. Adis is an … marriage license gregg countyWebFeb 18, 2024 · We describe an engineered exosome therapeutic candidate delivering an antisense oligonucleotide (ASO) targeting STAT6 (exoASO-STAT6), which selectively … nbc\u0027s red hood tv show